Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Respiratory Tract DiseasesLung DiseasesLung Diseases, InterstitialPulmonary Fibrosis

Interventions

DRUG

Interferon alpha oral lozenge

dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year

Trial Locations (1)

Texas Tech University Health Sciences Center, Lubbock

All Listed Sponsors

collaborator

Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

INDUSTRY

lead

Texas Tech University Health Sciences Center

OTHER

NCT01442779 - Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter